A clinical trial to study the drug Mullangi Chooranam in patients having Peptic Ulcer disease

Phase II non randomised open clinical evaluation of mullangi chooranam in eri gunmam (peptic ulcer disease) patients (both gender of age between 18 to 50)attendind opd at AAGHIM attached with GSMC

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2019/09/021198

Enrollment

Registered

2019-09-12

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K279- Peptic ulcer, site unspecified, unspecified as acute or chronic, without hemorrhage or perforation

Interventions

Intervention1: Mullangi chooranam: 2gm twice a day with butter milk for 28 days Control Intervention1: Nil: Nil

Eligibility

Inclusion criteria

Inclusion criteria: Duration of illness not more than 10 years Burning epigastric pain Abdominal bloating nausea anorexia vommiting

Exclusion criteria

Exclusion criteria: Pyloric stenosis carcinoma stomach acute abdominal colic gastric obstruction cholelithiasis pancreatitis appendicitis renal colic

Design outcomes

Primary

Measure	Time frame
The outcome of the treatment is mainly assessed by reduction in clinical symptoms by ulcer index score before and after treatment.Timepoint: 1 year	—

Secondary

Measure	Time frame
Treatment will be assessed by using endoscopy.Timepoint: 1 year	—

Countries

India

Contacts

Public ContactDr sowmiya K

Government siddha medical college

Mmsankar2000@gmail.com9445716802

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026